Download
00259_2024_Article_6920.pdf 1,38MB
WeightNameValue
1000 Titel
  • Utility of pre-procedural [99mTc]TcMAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation
1000 Autor/in
  1. Lam, Marnix |
  2. Garin, Etienne |
  3. Haste, Paul |
  4. Denys, Alban |
  5. Geller, Brian |
  6. Kappadath, S. Cheenu |
  7. Turkmen, Cuneyt |
  8. Sze, Daniel Y. |
  9. Alsuhaibani, Hamad Saleh |
  10. Herrmann, Ken |
  11. Maccauro, Marco |
  12. Cantasdemir, Murat |
  13. Dreher, Matthew |
  14. Fowers, Kirk D. |
  15. Gates, Vanessa |
  16. Salem, Riad |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-27
1000 Erschienen in
1000 Quellenangabe
  • 52(2):744-755
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00259-024-06920-6 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732885/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>Pre-treatment [<jats:sup>99m</jats:sup>Tc]TcMAA-based radioembolization treatment planning using multicompartment dosimetry involves the definition of the tumor and normal tissue compartments and calculation of the prescribed absorbed doses. The aim was to compare the real-world utility of anatomic and [<jats:sup>99m</jats:sup>Tc]TcMAA-based segmentation of tumor and normal tissue compartments.</jats:p> </jats:sec> <jats:sec> <jats:title>Materials and methods</jats:title> <jats:p>Included patients had HCC treated by glass [<jats:sup>90</jats:sup>Y]yttrium microspheres, ≥ 1 tumor, ≥ 3 cm diameter and [<jats:sup>99m</jats:sup>Tc]TcMAA SPECT/CT imaging before treatment. Segmentation was performed retrospectively using dedicated dosimetry software: (1) anatomic (diagnostic CT/MRI-based), and (2) [<jats:sup>99m</jats:sup>Tc]TcMAA threshold-based (i.e., using an activity-isocontour threshold). CT/MRI was co-registered with [<jats:sup>99m</jats:sup>Tc]TcMAA SPECT/CT. Logistic regression and Cox regression, respectively, were used to evaluate relationships between total perfused tumor absorbed dose (TAD) and objective response rate (ORR) and overall survival (OS). In a subset-analysis pre- and post-treatment dosimetry were compared using Bland-Altman analysis and Pearson’s correlation coefficient.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 209 patients were enrolled. Total perfused tumor and normal tissue volumes were larger when using anatomic versus [<jats:sup>99m</jats:sup>Tc]TcMAA threshold segmentation, resulting in lower absorbed doses. mRECIST ORR was higher with increasing total perfused TAD (odds ratio per 100 Gy TAD increase was 1.22 (95% CI: 1.01–1.49; <jats:italic>p</jats:italic> = 0.044) for anatomic and 1.19 (95% CI: 1.04–1.37; <jats:italic>p</jats:italic> = 0.012) for [<jats:sup>99m</jats:sup>Tc]TcMAA threshold segmentation. Higher total perfused TAD was associated with improved OS (hazard ratio per 100 Gy TAD increase was 0.826 (95% CI: 0.714–0.954; <jats:italic>p</jats:italic> = 0.009) and 0.847 (95% CI: 0.765–0.936; <jats:italic>p</jats:italic> = 0.001) for anatomic and [<jats:sup>99m</jats:sup>Tc]TcMAA threshold segmentation, respectively). For pre- vs. post-treatment dosimetry comparison, the average bias for total perfused TAD was + 11.5 Gy (95% limits of agreement: -227.0 to 250.0) with a strong positive correlation (Pearson’s correlation coefficient = 0.80).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Real-world data support [<jats:sup>99m</jats:sup>Tc]TcMAA imaging to estimate absorbed doses prior to treatment of HCC with glass [<jats:sup>90</jats:sup>Y]yttrium microspheres. Both anatomic and [<jats:sup>99m</jats:sup>Tc]TcMAA threshold methods were suitable for treatment planning.</jats:p> </jats:sec> <jats:sec> <jats:title>Trial registration number</jats:title> <jats:p>NCT03295006.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Glass/chemistry [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Radiometry [MeSH]
lokal Yttrium Radioisotopes/therapeutic use [MeSH]
lokal Original Article
lokal Microspheres [MeSH]
lokal Liver Neoplasms/pathology [MeSH]
lokal Male [MeSH]
lokal Single Photon Emission Computed Tomography Computed Tomography [MeSH]
lokal Carcinoma, Hepatocellular/radiotherapy [MeSH]
lokal Female [MeSH]
lokal Liver Neoplasms/diagnostic imaging [MeSH]
lokal Adult [MeSH]
lokal Albumins [MeSH]
lokal Humans [MeSH]
lokal Hepatocellular carcinoma
lokal Carcinoma, Hepatocellular/pathology [MeSH]
lokal Segmentation
lokal Retrospective Studies [MeSH]
lokal Technetium Tc 99m Aggregated Albumin [MeSH]
lokal Middle Aged [MeSH]
lokal Radioembolization
lokal Dosimetry
lokal Radiotherapy Planning, Computer-Assisted/methods [MeSH]
lokal Carcinoma, Hepatocellular/diagnostic imaging [MeSH]
lokal Liver Neoplasms/radiotherapy [MeSH]
lokal Yttrium-90
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-4902-9790|https://frl.publisso.de/adhoc/uri/R2FyaW4sIEV0aWVubmU=|https://frl.publisso.de/adhoc/uri/SGFzdGUsIFBhdWw=|https://frl.publisso.de/adhoc/uri/RGVueXMsIEFsYmFu|https://frl.publisso.de/adhoc/uri/R2VsbGVyLCBCcmlhbg==|https://frl.publisso.de/adhoc/uri/S2FwcGFkYXRoLCBTLiBDaGVlbnU=|https://frl.publisso.de/adhoc/uri/VHVya21lbiwgQ3VuZXl0|https://frl.publisso.de/adhoc/uri/U3plLCBEYW5pZWwgWS4=|https://frl.publisso.de/adhoc/uri/QWxzdWhhaWJhbmksIEhhbWFkIFNhbGVo|https://frl.publisso.de/adhoc/uri/SGVycm1hbm4sIEtlbg==|https://frl.publisso.de/adhoc/uri/TWFjY2F1cm8sIE1hcmNv|https://frl.publisso.de/adhoc/uri/Q2FudGFzZGVtaXIsIE11cmF0|https://frl.publisso.de/adhoc/uri/RHJlaGVyLCBNYXR0aGV3|https://frl.publisso.de/adhoc/uri/Rm93ZXJzLCBLaXJrIEQu|https://frl.publisso.de/adhoc/uri/R2F0ZXMsIFZhbmVzc2E=|https://frl.publisso.de/adhoc/uri/U2FsZW0sIFJpYWQ=
1000 Hinweis
  • DeepGreen-ID: 62e650eeb6c34430add44664cbccd16f ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. BTG International/Boston Scientific Corporation |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer BTG International/Boston Scientific Corporation |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6508186.rdf
1000 Erstellt am 2025-02-06T16:37:46.606+0100
1000 Erstellt von 322
1000 beschreibt frl:6508186
1000 Zuletzt bearbeitet 2025-09-12T05:20:28.609+0200
1000 Objekt bearb. Fri Sep 12 05:20:28 CEST 2025
1000 Vgl. frl:6508186
1000 Oai Id
  1. oai:frl.publisso.de:frl:6508186 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source